Hong Kong Stock Exchange · Healthcare
Invest in HUTCHMED (China) stock from India
Indian and foreign residents can buy HUTCHMED (China) (13) shares directly through Paasa.
By Paasa · Updated
HUTCHMED (China) at a glance
- Price
- HK$23.06+HK$0.76 (3.41%)
- Market cap
- HK$20.04B
- Day range
- HK$21.96 – HK$23.20
- P/E
- 158.86
- Dividend yield
- None
- Volume
- 4.64M
- 1 month
- +16.29%
- 6 months
- +5.39%
- YTD
- +11.83%
- 1 year
- -6.26%
- 5 years
- -59.54%
HUTCHMED (China) statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $548.5M | $630.2M | $838.0M | $426.4M | $356.1M |
| Gross profit | $63.9M | $281.3M | $151.6M | $115.3M | $97.9M |
| Operating income | −$39.2M | −$40.6M | $18.4M | −$407.7M | −$328.3M |
| Net income | $456.9M | $37.7M | $100.8M | −$360.8M | −$194.6M |
| Earnings per share | $0.52 | $0.04 | $0.12 | −$0.43 | −$0.25 |
| EBITDA | −$25.9M | $14.1M | $67.3M | −$401.1M | −$321.1M |
| Total assets | $1.8B | $1.3B | $1.3B | $1.0B | $1.4B |
| Total debt | $97.9M | $89.8M | $86.1M | $27.0M | $39.0M |
| Cash and short-term investments | $1.4B | $836.1M | $886.3M | $631.0M | $1.0B |
| Shareholders' equity | $1.2B | $759.9M | $730.5M | $610.4M | $986.9M |
| Operating cash flow | −$64.8M | $497.0K | $219.3M | −$268.6M | −$204.2M |
| Free cash flow | −$78.9M | −$17.4M | $186.6M | −$305.3M | −$221.0M |
| Capital expenditure | −$14.2M | −$17.9M | −$32.6M | −$36.7M | −$16.8M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in USD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Keymed Biosciences | 2162.HK | HK$81.00 | HK$23.86B |
| InnoCare Pharma | 9969.HK | HK$14.58 | HK$21.78B |
| Shanghai Conant Optical | 2276.HK | HK$37.10 | HK$17.94B |
| Grand Pharmaceutical | 0512.HK | HK$4.93 | HK$17.26B |
| United Laboratories International | 3933.HK | HK$7.91 | HK$15.58B |
| Shenzhen Hepalink Pharmaceutical | 9989.HK | HK$4.03 | HK$13.61B |
| CanSino Biologics | 6185.HK | HK$36.48 | HK$12.77B |
| Consun Pharmaceutical | 1681.HK | HK$15.02 | HK$12.60B |
Peers as grouped by the data provider. This is not an investment recommendation.
Analyst price targets
- Low
- —
- High
- —
- Median
- —
- Consensus
- —
Ratings: 3 buy · 1 hold · 0 sell. Consensus: Buy.
Published sell-side 12-month targets in HKD, aggregated by the data provider. They are not Paasa's view and not a forecast.
How to invest in HUTCHMED (China) from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to HKD when you buy.
Step 3
Search 13 and buy
Find HUTCHMED (China) by name or by its ticker, 13, and place your order. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
Why invest in HUTCHMED (China) from India
What HUTCHMED (China) does
HUTCHMED (China) Limited, a biopharmaceutical company established in 2000 and headquartered in Central, Hong Kong, focuses on the discovery, development, and commercialization of innovative targeted therapies and immunotherapies. The company primarily addresses cancer and immunological disorders, serving a global patient population in addition to Hong Kong. HUTCHMED (China) operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy HUTCHMED (China) stock from India?
Yes. Indian residents and NRIs can buy HUTCHMED (China) (13) shares directly through Paasa. HUTCHMED (China) is listed on the Hong Kong Stock Exchange, in the Drug Manufacturers - Specialty & Generic industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
Do I need to buy a full HUTCHMED (China) share?
Usually more than one, and not a fraction: many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. At HK$23.06 a share, size the order by the lot, not by the share.
What tax do I pay in India when I sell HUTCHMED (China) shares?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks. In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the HKD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.
Would my heirs owe estate tax on HUTCHMED (China) shares?
Hong Kong has no estate duty. That is the source-country side; the shares themselves pass on like any other asset you hold in your own name.